Takeda wins FDA nod for first-in-class blood cancer drug Mimrylo
Takeda has received FDA approval for Mimrylo, a first-in-class treatment for blood cancer. The approval strengthens Takeda's oncology portfolio with a novel mechanism of action.
Takeda
Services: Global biopharma; gastroenterology, oncology, neuroscience, rare diseases, plasma-derived therapies; R&D-driven with AI/ML and lab automation. | Leadership: — | Keywords: global pharma, GI, oncology, rare diseases, plasma, Japan
Company Info
Recent News
US FDA approves Takeda, Protagonist's drug for rare blood cancer
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
Insilico inks partnership via $600M biobuck collab with Takeda
Insilico inks partnership via $600M biobuck collab with Takeda — Fierce Biotech coverage of biopharma industry developments.
Takeda enters transitional year as new CEO seeks return to growth
For the 2026 fiscal year, Takeda anticipates declines in revenue and profit, highlighting what CEO-elect Julie Kim says is the need for the company to “invest in future growth.”